SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending as community members discuss potential impacts of trade disputes with Canada following the termination of trade talks. The community is also focused on the financial implications of Trump's cryptocurrency holdings and the ongoing construction of a new ballroom at the White House. Broader discussions involve political narratives around tariffs, the economy, and comparisons to historical figures.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending amid escalating US-China trade tensions, with Trump threatening tariffs and China vowing countermeasures. Community discussion revolves around the potential impact on the market and specific sectors. Investors are closely monitoring developments as the situation unfolds.

Trump For President

The Trump Crypto token ($TRUMP) is trending amid discussions about its performance and potential connection to Donald Trump's activities, including reports of family profits and market manipulation. Community members are debating the coin's long-term viability, potential for recovery, and its relationship to the broader crypto market. Some users are also discussing Trump's political actions and their potential impact on the token's value.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is trending amid community excitement, particularly around its availability and activity on Phantom Wallet. Discussions highlight the token's potential for gains, with some noting its relative stability compared to the broader market, while others are focused on entry points and risk management.

Moo Deng

Moo Deng ($MOODENG) is trending as traders discuss its potential for a pump, with some highlighting its low supply and recent listings; however, the coin's volatile price action and mixed sentiment are generating debate within the community, as some traders express concerns about potential manipulation.

The Syndicate Network enables developers to build and operate smart rollups—application-specific blockchains (appchains) with programmable, onchain smart sequencers. Anticipated to launch on September 17, 2025, Syndicate moves sequencing logic from centralized, offchain services into transparent smart contracts on Syndicate Network, allowing applications to customize their transaction ordering, fee structures, and governance models. The SYND token, with a fixed supply of 1 billion tokens, serves as both the native gas token for Syndicate Network and Commons Chain (Syndicate's L3 that settles on Base) and the governance token for the entire network. Originally deployed on Ethereum Mainnet with bridging to Base, SYND launches with 92% of supply minted at genesis and 8% distributed through programmatic emissions over four years. SYND functions as essential infrastructure for network operations and governance. As the gas token, appchain operators use SYND to pay for sequencing transactions, deploying sequencer contracts, and writing blocks to Syndicate Network. As the governance token, SYND holders control the network's direction through a Wyoming Decentralized Unincorporated Nonprofit Association (DUNA), which holds the 258.7 million token treasury. Token holders vote on treasury deployments, network upgrades, and strategic partnerships, ensuring the community maintains control over the ecosystem's evolution. Starting with emissions anticipated October 1, 2025, holders also stake SYND on Commons Chain to earn from an 80 million token pool distributed over 48 thirty-day epochs across three pools: the Base Pool (30%) provides returns proportional to stake amount and duration, the Performance Pool (30%) rewards stakers based on the success of appchains they back, and the Appchain Pool (40%) directly funds appchains based on fees generated and stake attracted. Token holders interact with SYND through standard web3 infrastructure for both staking and governance. After bridging tokens from Ethereum or Base to Commons Chain, holders deposit SYND into the staking contract and allocate their stake across appchains for 30-day epochs. Beginning October 31, 2025, stakers must allocate 100% of their stake to specific appchains, creating direct alignment between token holders and ecosystem growth. Staking rewards are calculated based on both the amount staked and the performance of backed appchains—holders who identify successful appchains early earn outsized returns from the Performance Pool. Beyond staking, token holders participate in governance decisions that shape the network's future, from treasury allocations to protocol upgrades, ensuring the community retains sovereignty over the infrastructure they use. The smart sequencer architecture enables appchains to evolve through smart contract upgrades rather than infrastructure changes—modifying everything from transaction ordering to fee distribution through simple module updates. As the network matures, SYND's role expands to securing Syndicate Network itself through proof-of-stake validation, with the economic model shifting from emission-driven to fee-driven as usage grows. The governance structure ensures that major decisions—from emission schedule adjustments to treasury disbursements for ecosystem development—remain under token holder control through the DUNA framework. This design aligns incentives across all participants: developers capture value through customized appchains, token holders earn returns by backing successful projects while governing the network's direction, and the broader ecosystem benefits from purpose-built chains with programmable economics and atomic cross-chain composability.

Syndicate

Syndicate (SYND) is trending amid community excitement and mentions of significant whale inflows, sparking discussion about potential adoption and a possible recovery from recent price declines within the DeFi space. Social media conversations suggest traders are closely monitoring SYND, citing its strong performance and increasing volume.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to recent FDA approval of their leukemia drug Revuforj, though a warning of potentially fatal side effects has tempered initial enthusiasm. The community is debating the significance of the warning label, with some arguing it's standard for such treatments and others expressing concern about its impact on adoption. Bullish investors believe the long-term fundamentals remain strong, while bears anticipate further downside.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to recent news of strong revenue growth, sparking community discussion around a potential short squeeze given its microfloat. Traders are closely watching for continued momentum and a potential breakout, while some caution against chasing the stock due to its history of volatility. Bullish sentiment is fueled by the company's financial performance and speculation about future growth catalysts.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending as Bitcoin approaches all-time highs, driving community discussion around potential price targets and market dynamics. Investors are closely monitoring Bitcoin's movements, analyzing technical indicators and potential resistance levels. Community members are also weighing in on factors like ETF inflows, regulatory developments, and the broader macroeconomic environment.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin ($AMRN) is trending amid speculation around a potential acquisition, particularly by Novartis, fueled by community analysis of SEC filings, partnerships, and upcoming presentations at the European Society of Cardiology (ESC) Congress. Discussions center on the potential for a buyout, as well as the value of their patent for cardiovascular health applications. Some investors point to technical indicators suggesting steady accumulation and an imminent breakout, while others remain skeptical of a turnaround given the company's history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders...

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets...

QGEN vs. ACAD: Which Stock Is the Better Value Option?

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Equity

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.


Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ACAD
Acadia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACAD News

ACADAcadia Pharmaceuticals Inc